OVERVIEW
Overcoming complexity in movement disorder research
Accurately capturing disease progression and treatment efficacy requires the right tools, expertise, and methodologies. Clario helps eliminate uncertainty, delivering high-quality, regulatory-compliant data to support successful trial outcomes.
SOLUTIONS AND EXPERTISE
Comprehensive solutions for movement disorder trials
Accurate and reliable endpoint assessments
Assessing disease-related changes can be complex, and inaccurate measurements can impact trial success. Our advanced imaging solutions – MRI, SPECT, and PET – enable precise biomarker identification and expert interpretation, providing confidence in your endpoint assessments.
- Early detection of disease-related changes
- Reliable endpoint data for regulatory submissions
- Expert neuroimaging interpretation for precise trial insights
Optimize COA selection and improve data quality
Selecting the right clinical outcome assessments (COAs) is critical to trial success. Our eCOA science team provides expert guidance to optimize protocol design, COA selection, and site training, enhancing compliance and data accuracy while minimizing errors.
- Expert guidance on COA selection
- eCOA solutions to improve compliance and reduce variability
- Robust site training to maintain data integrity
Capture objective movement data with wearable sensors
Traditional subjective scales may overlook subtle disease progression. Our Opal wearable sensors provide precise, objective movement measurements, enabling early detection and deeper clinical insights.
- Continuous, real-world movement monitoring
- Greater sensitivity to disease progression
- Objective, high-quality data to complement traditional assessments
Mitigate safety risks with expert monitoring
Investigational treatments for movement disorders can impact cardiovascular and pulmonary function, posing safety concerns. Clario’s cardiac safety and respiratory experts develop tailored monitoring strategies to detect risks early and support patient safety.
- QT prolongation and cardiovascular risk monitoring
- Pulmonary function assessments to detect respiratory side effects
- Integrated safety solutions across the trial lifecycle
Partner with Clario for confident, data-driven decisions
Let’s work together to drive meaningful progress in movement disorder research.
We have supported over 200 movement disorder trials, contributing to more than 25 FDA and EMA drug approvals. With a dedicated team of 30+ neuroscientists, biomechanists, and data scientists, we deliver end-to-end solutions that improve data accuracy, ensure regulatory compliance, and enhance trial efficiency.
Our experts are committed to providing the insights and support you need at every stage of your study.